5 Penny Stocks with Potential to Rise 1000 Percent

2. Allogene therapeutics (NASDAQ:ALLO)

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the penny stocks with potential to rise 1000 percent.

Allogene Therapeutics said on March 12, 2026, that its lead program, cemacabtagene ansegedleucel, or cema-cel, remains on track in the pivotal Phase 2 ALPHA3 trial in first-line consolidation for large B-cell lymphoma. The company said the study is the first designed to test whether early, measurable residual disease-guided consolidation with cema-cel can prevent recurrence in LBCL, and that it is enrolling across more than 60 activated clinical trial sites in academic and community cancer centers, including sites outside the United States. An interim futility analysis is planned for April 2026 and will compare MRD clearance rates and early safety outcomes between the cema-cel arm and observation.

The company also highlighted progress in autoimmune disease with ALLO-329, a dual CD19/CD70 AlloCAR T candidate that uses its Dagger technology to reduce or potentially eliminate conventional lymphodepletion. Allogene said the Phase 1 RESOLUTION basket trial is enrolling in dose escalation across indications, including systemic lupus erythematosus, lupus nephritis, scleroderma, and inflammatory myositis, with initial data from the first dosing cohort expected in June 2026.

Allogene Therapeutics, Inc. (NASDAQ:ALLO)  is a clinical-stage biotechnology company developing off-the-shelf allogeneic CAR T cell products for cancer and autoimmune disease.